Bovine papillomavirus type 1 (BPV1) and BPV2 are closely related serotypes

Virology

Volumn 393, Issue 1, 2009, Pages 1-6

  Shafti Keramat, Saeed ^a   Schellenbacher, Christina ^a   Handisurya, Alessandra ^a   Christensen, Neil ^c   Reininger, Bärbel ^b   Brandt, Sabine ^d   Kirnbauer, Reinhard ^a  

^a Division of Immunology Allergy and Infectious Diseases (DIAID)   (Austria)

^b Department of Dermatology   (Austria)

^c PENN STATE CANCER INSTITUTE   (United States)

^d UNIVERSITY OF VETERINARY MEDICINE   (Austria)

Author keywords

Bovine papillomavirus (BPV); Fibropapilloma; Sarcoids; Serotypes; Vaccine

Indexed keywords

ADJUVANT; ALUMINUM HYDROXIDE; ANTISERUM; CAPSID PROTEIN; EPITOPE; MONOCLONAL ANTIBODY; WART VIRUS VACCINE;

ANIMAL CELL; ARTICLE; BOVINE PAPILLOMAVIRUS TYPE 1; BOVINE PAPILLOMAVIRUS TYPE 2; CHEMOPROPHYLAXIS; CONTROLLED STUDY; COW; FIBROMA; HORSE; HUMAN; HUMAN CELL; INSECT CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN EXPRESSION; SARCOIDOSIS; SEROTYPE; VACCINATION; VIRION; VIRUS INFECTION; VIRUS LIKE AGENT; VIRUS NEUTRALIZATION;

ANIMALS; ANTIBODIES, VIRAL; BOVINE PAPILLOMAVIRUS 1; CAPSID PROTEINS; CATTLE; CATTLE DISEASES; CROSS REACTIONS; HORSE DISEASES; HORSES; NEUTRALIZATION TESTS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; RABBITS; VACCINES, VIROSOME;

BOVINE PAPILLOMAVIRUS; BOVINE PAPILLOMAVIRUS TYPE 1; EQUIDAE; HEXAPODA; MIRIDAE;

EID: 70349238565     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2009.07.036     Document Type: Article

References (26)

1. Breitburd F., Kirnbauer R., Hubbert N.L., Nonnenmacher B., Trin-Dinh-Desmarquet C., Orth G., Schiller J.T., and Lowy D.R. Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J. Virol. 69 6 (1995) 3959-3963
2. Brown D.R., Kjaer S.K., Sigurdsson K., Iversen O.E., Hernandez-Avila M., Wheeler C.M., Perez G., Koutsky L.A., Tay E.H., Garcia P., Ault K.A., Garland S.M., Leodolter S., Olsson S.E., Tang G.W., Ferris D.G., Paavonen J., Steben M., Bosch F.X., Dillner J., Joura E.A., Kurman R.J., Majewski S., Munoz N., Myers E.R., Villa L.L., Taddeo F.J., Roberts C., Tadesse A., Bryan J., Lupinacci L.C., Giacoletti K.E., Sings H.L., James M., Hesley T.M., and Barr E. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J. Infect. Dis. 199 7 (2009) 926-935
3. Buck C.B., Pastrana D.V., Lowy D.R., and Schiller J.T. Generation of HPV pseudovirions using transfection and their use in neutralization assays. Methods Mol. Med. 119 (2005) 445-462
4. Campo M.S. Vaccination against papillomavirus in cattle. Clin. Dermatol. 15 2 (1997) 275-283
5. Campo M.S., Jarrett W.F., O'Neil W., and Barron R.J. Latent papillomavirus infection in cattle. Res. Vet. Sci. 56 2 (1994) 151-157
6. Cheng G., Icenogle J.P., Kirnbauer R., Hubbert N.L., St Louis M.E., Han C., Svare E.I., Kruger Kjaer S., Lowy D.R., and Schiller J.T. Divergent human papillomavirus type 16 variants are serologically cross-reactive. J. Inf. Dis. 172 (1995) 1584-1587
7. Christensen N.D., and Kreider J.W. Monoclonal antibody neutralization of BPV-1. Virus Res. 28 2 (1993) 195-202
8. Day P.M., Thompson C.D., Buck C.B., Pang Y.Y., Lowy D.R., and Schiller J.T. Neutralization of human papillomavirus with monoclonal antibodies reveals different mechanisms of inhibition. J. Virol. 81 16 (2007) 8784-8792
9. Dvoretzky I., Shober R., Chattopadhyay S.K., and Lowy D.R. A quantitative in vitro focus assay for bovine papilloma virus. Virology 103 2 (1980) 369-375
10. Embers M.E., Budgeon L.R., Pickel M., and Christensen N.D. Protective immunity to rabbit oral and cutaneous papillomaviruses by immunization with short peptides of L2, the minor capsid protein. J. Virol. 76 19 (2002) 9798-9805
11. Frazer I.H. Interaction of human papillomaviruses with the host immune system: a well evolved relationship. Virology 384 2 (2009) 410-414
12. Ghim S.J., Young R., and Jenson A.B. Antigenicity of bovine papillomavirus type 1 (BPV-1) L1 virus-like particles compared with that of intact BPV-1 virions. J. Gen. Virol. 77 Pt 2 (1996) 183-188
13. Howley P.M., and Lowy D.R. Papillomavirus. In: Knipe D.M., and Howley P.M. (Eds). Fields Virology. 5 ed. 2 (2007), Lippincott Williams and Wilkins, Philadelphia 2299-2354
14. Kirnbauer R., Booy F., Cheng N., Lowy D.R., and Schiller J.T. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc. Natl. Acad. Sci. U. S. A. 89 24 (1992) 12180-12184
15. Kirnbauer R., Hubbert N.L., Wheeler C.M., Becker T.M., Lowy D.R., and Schiller J.T. A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16. J. Natl. Cancer Inst. 86 7 (1994) 494-499
16. Kirnbauer R., Chandrachud L., O'Neil B., Wagner E., Grindlay G., Armstrong A., McGarvie G., Schiller J., Lowy D., and Campo M. Virus-like particles of bovine papillomavirus type-4 in prophylactic and therapeutic immunization. Virology 219 1 (1996) 37-44
17. Nasir L., and Campo M.S. Bovine papillomaviruses: their role in the aetiology of cutaneous tumours of bovids and equids. Vet. Dermatol. 19 5 (2008) 243-254
18. Paavonen J., Jenkins D., Bosch F.X., Naud P., Salmeron J., Wheeler C.M., Chow S.N., Apter D.L., Kitchener H.C., Castellsague X., de Carvalho N.S., Skinner S.R., Harper D.M., Hedrick J.A., Jaisamrarn U., Limson G.A., Dionne M., Quint W., Spiessens B., Peeters P., Struyf F., Wieting S.L., Lehtinen M.O., and Dubin G. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 369 9580 (2007) 2161-2170
19. Pastrana D.V., Gambhira R., Buck C.B., Pang Y.Y., Thompson C.D., Culp T.D., Christensen N.D., Lowy D.R., Schiller J.T., and Roden R.B. Cross-neutralization of cutaneous and mucosal papillomavirus types with anti-sera to the amino terminus of L2. Virology 337 2 (2005) 365-372
20. Roden R.B., Weissinger E.M., Henderson D.W., Booy F., Kirnbauer R., Mushinski J.F., Lowy D.R., and Schiller J.T. Neutralization of bovine papillomavirus by antibodies to L1 and L2 capsid proteins. J. Virol. 68 11 (1994) 7570-7574
21. Roden R., Greenstone H., Kirnbauer R., Booy F., Joel J., Lowy D., and Schiller J. In vitro generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotype. J. Virol. 70 9 (1996) 5875-5883
22. Roden R.B., Armstrong A., Haderer P., Christensen N.D., Hubbert N.L., Lowy D.R., Schiller J.T., and Kirnbauer R. Characterization of a human papillomavirus type 16 variant-dependent neutralizing epitope. J. Virol. 71 8 (1997) 6247-6252
23. Shafti-Keramat S., Handisurya A., Kriehuber E., Meneguzzi G., Slupetzky K., and Kirnbauer R. Different heparan sulfate proteoglycans serve as cellular receptors for human papillomaviruses. J. Virol. 77 24 (2003) 13125-13135
24. Suzich J.A., Ghim S., Palmer-Hill F.J., White W.I., Tamura J.K., Bell J., Newsome J.A., Jenson A.B., and Schlegel R. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 11553-11557
25. Villa L.L., Costa R.L., Petta C.A., Andrade R.P., Ault K.A., Giuliano A.R., Wheeler C.M., Koutsky L.A., Malm C., Lehtinen M., Skjeldestad F.E., Olsson S.E., Steinwall M., Brown D.R., Kurman R.J., Ronnett B.M., Stoler M.H., Ferenczy A., Harper D.M., Tamms G.M., Yu J., Lupinacci L., Railkar R., Taddeo F.J., Jansen K.U., Esser M.T., Sings H.L., Saah A.J., and Barr E. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 6 5 (2005) 271-278
26. Wheeler C.M., Kjaer S.K., Sigurdsson K., Iversen O.E., Hernandez-Avila M., Perez G., Brown D.R., Koutsky L.A., Tay E.H., Garcia P., Ault K.A., Garland S.M., Leodolter S., Olsson S.E., Tang G.W., Ferris D.G., Paavonen J., Steben M., Bosch F.X., Dillner J., Joura E.A., Kurman R.J., Majewski S., Munoz N., Myers E.R., Villa L.L., Taddeo F.J., Roberts C., Tadesse A., Bryan J., Lupinacci L.C., Giacoletti K.E., James M., Vuocolo S., Hesley T.M., and Barr E. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J. Infect Dis. 199 7 (2009) 936-944